Levomilnacipran Hydrochloride Patent Expiration
Levomilnacipran Hydrochloride is used for treating Major Depressive Disorder (MDD) It was first introduced by Abbvie Inc
Levomilnacipran Hydrochloride Patents
Given below is the list of patents protecting Levomilnacipran Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Fetzima | US8865937 | Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide | May 23, 2032 | Abbvie |
| Fetzima | US8481598 | Stable dosage forms of levomilnacipran | Mar 02, 2031 | Abbvie |
| Fetzima | USRE43879 | Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug | Jan 11, 2026 | Abbvie |
Levomilnacipran Hydrochloride's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List